Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Business Cocktail

Sep 20, 2017

Table of Contents

Chinese pharma company Shanghai Fosun to acquire 74% stake in Indian company Gland Pharma for $1.09 billion

In July last year Chinese company Shanghai Fosun Pharmaceutical announced to acquire 74% per cent stake in Gland Pharma (Hyderabad-based Company) for not more than USD 1.09 billion. Initially the deal was set to acquire 86.08 per cent stake for USD 1.26 billion but it got revised as per the latest regulatory filing of the company.

Teva Pharmaceutical sell last of its Women’s Health Portfolio, gains another $2.48 billion

To progress repayment of term loan debt Teva Pharmaceutical has recently announced that it has entered into two agreements to sell the remaining resources of its specialty global women’s health business for USD 1.38 billion. Earning from these sales, combined with earnings from the recently announced sale of PARAGARD is around USD 2.48 billion.

Downloads

Article in PDF

Recent Articles

FDA Grants Orphan Status to MDL-101 for LAMA2-CMD; Pfizer’s ABRYSVO Approved for High-Risk Adults...

Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy

X4 Pharmaceuticals’ XOLREMDI FDA Approval; ONO to Acquire Deciphera Pharmaceuticals; Johnson &...

Notizia

Exploring the Nonalcoholic Steatohepatitis (NASH) Landscape

Gates Foundation invests in Immunocore to fuel infectious disease R&D

Immunocore which is primarily known for its work in oncology is expanding its horizon into tuberculosis and HIV treatment. Bill & Melinda Gates Foundation is investing up to USD 40 million in Immunocore to fuel its research into the use of T cell receptor (TCR)-based therapeutics to effectively treat tuberculosis and HIV.

Disarm Therapeutics announces completion of Series A funding of USD 30 million

Disarm Therapeutics has recently announced completion of Series A funding of USD 30 million as it looks for a breakthrough approach in axonal degeneration. Funding is led by Atlas Venture and some co-investors like Lightstone Ventures and AbbVie Ventures.